a day ago
Paysign price target raised to $8 from $7 at DA Davidson
DA Davidson analyst Peter Heckmann raised the firm's price target on Paysign (PAYS) to $8 from $7 and keeps a Buy rating on the shares. Last week, Paysign announced the company had been awarded 132 established plasma donation centers through an expansion of a relationship with a major plasma collection company, and the firm believes this will increase the company's total plasma locations to 613 centers, a 27% increase over the 484 locations served at the end of Q1, the analyst tells investors in a research note.
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders' Hot Stocks on TipRanks >>
Read More on PAYS:
Disclaimer & DisclosureReport an Issue
PaySign's Strong Growth Potential and Strategic Positioning in Healthcare: A Buy Rating by Gary Prestopino
Paysign participates in a conference call with DA Davidson
PaySign's Strong Growth Potential and Strategic Positioning Earns Buy Rating from Analyst
Paysign awarded 132 plasma donation centers
Paysign price target raised to $6-$7 range from $5 at Barrington
